6.1.2.3. Incretin mimetics
Please see the NHSGGC Diabetes Guidelines for further information.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes as part of a triple therapy in patients with inadequate glycaemic control on two oral anti-diabetic drugs.
Prescribing Notes:
- Dulaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes for the following indications:
- as a third-line antidiabetic agent in combination with metformin and a sulfonylurea or metformin and pioglitazone.
- in combination with basal insulin, with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Prescribing Notes:
- Liraglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
For use in the management of obesity, see section 4.5.2
Restrictions:
Use in the treatment of type 2 diabetes mellitus (T2DM) is restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes for use in addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.
Prescribing Notes:
- Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes in accordance with the prescribing notes below.
Prescribing Notes:
- Restricted to third line treatment of type-2 diabetes mellitus in combination with other agents.
- NHSGGC Diabetes Guidelines click here
Restrictions:
Restricted to initiation by Consultant Diabetologists for use in patients who are uncontrolled on basal insulin analogues (glycosylated haemoglobin [HbA1c] >7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.
Prescribing Notes:
- Liraglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
Restrictions:
Use in the treatment of type 2 diabetes mellitus (T2DM) is restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes for use in addition to other anti-diabetic medicines, or as an add-on to basal insulin.
Prescribing Notes:
- Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
Restrictions:
To be used as triple therapy in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.
Restricted to initiation by clinicians in primary care or the acute setting who are experienced in the treatment of diabetes.
Prescribing Notes:
- For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- NHSGGC Diabetes Guidelines click here